VivoSim Labs, Inc. (NASDAQ:VIVS) Sees Significant Increase in Short Interest

VivoSim Labs, Inc. (NASDAQ:VIVS) was the target of a significant increase in short interest in the month of January. As of January 30th, there was short interest totaling 774,911 shares, an increase of 9,129.5% from the January 15th total of 8,396 shares. Approximately 30.5% of the company’s shares are sold short. Based on an average daily volume of 9,185,858 shares, the short-interest ratio is currently 0.1 days. Based on an average daily volume of 9,185,858 shares, the short-interest ratio is currently 0.1 days. Approximately 30.5% of the company’s shares are sold short.

Institutional Trading of VivoSim Labs

A hedge fund recently bought a new stake in VivoSim Labs stock. Two Sigma Investments LP bought a new position in VivoSim Labs, Inc. (NASDAQ:VIVS) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned approximately 0.89% of VivoSim Labs at the end of the most recent reporting period. 8.23% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of VivoSim Labs in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, VivoSim Labs presently has a consensus rating of “Sell”.

VivoSim Labs Stock Performance

VivoSim Labs stock opened at $1.92 on Thursday. The company has a 50-day simple moving average of $2.07 and a 200-day simple moving average of $2.37. VivoSim Labs has a one year low of $1.41 and a one year high of $21.96. The firm has a market capitalization of $5.01 million, a P/E ratio of -0.44 and a beta of 1.21.

VivoSim Labs (NASDAQ:VIVS) last issued its quarterly earnings data on Wednesday, February 11th. The company reported ($1.03) earnings per share (EPS) for the quarter. VivoSim Labs had a negative return on equity of 28.83% and a negative net margin of 1,413.57%.The business had revenue of $0.03 million for the quarter.

VivoSim Labs Company Profile

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.